The official blog of the Lung Institute.

Lung Institute Encourages Public to Quit Smoking and Get Screened for Cancer Before It’s Too Late

29 Oct 2013
| Under Press | Posted by | 0 Comments
Lung Institute Encourages Public to Quit Smoking

Each Week in October, Lung Institute’s Medical Staff is Giving FREE Pulmonary Health Advice in Honor of Healthy Lung Month

Tampa, Fla. (October 29, 2013) – On average, smokers die 10 years earlier than nonsmokers, and cigarette smoking is responsible for more than 480,000 deaths per year in the United States. Because of this reality, and in support of Healthy Lung Month, the Lung Institute is asking the public to put down cigarettes for good and to get screened for lung cancer.

When people think of getting screened for lung cancer, they think of x-ray machines and sputum tests. However, contrary to popular belief, these methods are not the only ways to test for cancer. According to the American Lung Association, an effective method of identifying lung cancer is the low dose computed tomography (CT) scan.

However, not everyone is a candidate for the CT scan screening for lung cancer, and there are some risks. Read these qualifying factors below to learn who is likely a candidate for this specialized test.

  • Candidates must be a current or former smoker
  • Must fall between the ages of 55 and 74
  • And they must have a smoking history of at least 30-pack years (One a pack a day for 30 years or the equivalent)

People that fit within the criteria above are at the highest risk for developing lung disease, and they should visit their doctor to discuss further screening options. For people that are current smokers, but do not fit the criteria, prevention starts with quitting. Visit our website at LungInstitute.com to learn more tips to quit smoking. By sharing this information with a smoker, another life could be saved.

About Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Tampa, Fla., Nashville, Tenn., Scottsdale, Ariz., Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.